

ZENTRIX®

TIRZEPATIDE

Solution for Injection in Multi-Dose Vial
A long-acting dual GIP and GLP-1 receptor agonist
designed to support metabolic regulation, appetite
control and weight management.

60 MG

Manufactured in Switzerland

COMPOSITION

Each ZENTRIX® TIRZEPATIDE multi-dose vial contains:

- 60 mg Tirzepatide.

Total peptide content: 60 mg

Each vial contains 3 ml sterile solution.

The vial provides 5 full doses of 0.6 ml.

Each 0.6 ml delivers:

- 15 mg Tirzepatide.

DOSING GUIDE

10 units

- 2.5 mg Tirzepatide.

20 units

- 5 mg Tirzepatide.

30 units

- 7.5 mg Tirzepatide.

40 units

- 10 mg Tirzepatide.

50 units

- 12.5 mg Tirzepatide.

60 units

- 15 mg Tirzepatide.

RECOMMENDED DOSING PROTOCOL

ZENTRIX® Tirzepatide is administered once weekly.

Start with a lower dose to minimise gastrointestinal side effects.

Initial phase (Weeks 1-4):

- 2.5 mg Tirzepatide

Dose: 10 units once weekly

Dose escalation phase (Weeks 5-8):

- 5 mg Tirzepatide

Dose: 20 units once weekly

Intermediate phase (Weeks 9-12):

- 7.5 mg Tirzepatide

Dose: 30 units once weekly

Standard therapeutic dose:

- 10 mg Tirzepatide.

Dose: 40 units once weekly

Higher therapeutic dose (if required):

- 12.5 mg Tirzepatide

Dose: 50 units once weekly

Maximum recommended dose:

- 15 mg Tirzepatide

Dose: 60 units once weekly

Do not exceed 60 units within any 7-day period.

INSTRUCTIONS FOR USE

Please read these instructions carefully before using your ZENTRIX® TIRZEPATIDE multi-dose vial. Do not use the vial without proper instruction from a qualified healthcare professional. If you are blind or have poor eyesight and cannot read the dose counter, ask a trained person with good eyesight to assist you.

ABOUT YOUR VIAL

Your ZENTRIX® multi-dose vial is a sterile solution designed for accurate subcutaneous peptide administration.

- Each vial contains 60 mg Tirzepatide.
- Each vial contains 3 ml sterile solution.

BEFORE EACH INJECTION

Always check that:

The vial label reads ZENTRIX® TIRZEPATIDE

The solution is clear and colourless.

The product is within its expiry date.

Do not use the vial if the solution appears cloudy, discoloured, or contains visible particles.

IMPORTANT INJECTION GUIDANCE

Always use a new needle for every injection.

This helps prevent:

- Blocked needles.
- Contamination.
- Infection.
- Inaccurate dosing.

SELECTING YOUR DOSE

Draw the correct dose into the syringe according to the dosage table.

NEEDLE SAFETY

Never use a bent or damaged needle. Do not attempt to place the inner needle cap back on the needle after injection, as this may cause accidental needle-stick injury. Dispose of used needles in an approved sharps container.

STORAGE

Store the vial:

Before first use 2 °C - 8 °C (refrigerated)

After first use Store below 25 °C.

Protect from direct sunlight. Do not freeze. Discard the vial 28 days after first use, even if solution remains.

CONTRAINDICATIONS

Do not use ZENTRIX® TIRZEPATIDE if:

- You are allergic to tirzepatide or any component of the formulation;
- You have a personal or family history of medullary thyroid carcinoma (MTC);
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
- The solution appears cloudy, discoloured, or contains visible particles;
- The product has expired.

Do not use the vial if the packaging appears damaged or tampered with.

WARNINGS AND PRECAUTIONS

Consult a healthcare professional before use if you:

- Have a history of pancreatitis;
- Have severe gastrointestinal disease;
- Have gallbladder disease;
- Have kidney impairment;
- Have diabetic retinopathy.

Tirzepatide may slow gastric emptying and affect absorption of oral medications.

USE WITH OTHER MEDICINES

Tell your healthcare professional if you are using:

- Insulin;
- Sulfonylurea medications;
- Other GLP-1 receptor agonists.

Using tirzepatide with insulin or insulin secretagogues may increase the risk of hypoglycaemia.

Dose adjustments of other medications may be required.

PREGNANCY AND BREASTFEEDING

The safety of tirzepatide during pregnancy or breastfeeding has not been established. Do not use this product if you are:

- Pregnant;
- Planning pregnancy;
- Breastfeeding.

Unless advised by a healthcare professional.

Women of childbearing potential should use effective contraception while using this product.

USE IN CHILDREN AND ADOLESCENTS

Not recommended for individuals under 18 years of age, as safety and efficacy have not been established.

USE IN OLDER ADULTS

No specific dose adjustment is generally required for older adults. However, monitoring may be recommended in individuals with underlying health conditions.

INJECTION SITE GUIDANCE

Recommended injection sites include:

Abdomen (at least 5 cm away from the navel); Upper outer thigh; Upper arm.

Rotate injection sites weekly to minimise irritation. Avoid injecting into bruised skin, scar tissue, or inflamed areas.

OVERDOSE

Using more than the recommended dose may increase the likelihood of side effects such as:

Severe nausea; Vomiting; Hypoglycaemia; Dehydration.

If a significantly higher dose has been administered, consult a healthcare professional.

MISSED DOSE

If a dose is missed and less than 4 days have passed, administer the dose as soon as possible. If more than 4 days have passed, skip the missed dose and administer the next dose at the regularly scheduled time. Do not administer double doses.

POSSIBLE SIDE EFFECTS

Like all injectable products, ZENTRIX® TIRZEPATIDE may cause side effects, although not everybody experiences them.

Very Common (may affect more than 1 in 10 users)

Nausea; Diarrhoea; Reduced appetite; Vomiting.

Common (may affect up to 1 in 10 users)

Constipation; Indigestion; Abdominal discomfort; Fatigue Injection site reactions.

Uncommon (may affect up to 1 in 100 users)

Gallbladder disease; Dizziness; Increased heart rate; Injection site inflammation.

Rare (may affect up to 1 in 1,000 users)

Pancreatitis; Severe dehydration.

Very Rare (may affect up to 1 in 10,000 users)

Severe allergic reaction; Hypersensitivity reaction.

Seek immediate medical attention if symptoms of pancreatitis or severe allergic reaction occur.

REPORTING SIDE EFFECTS

If you experience any side effects, talk to your healthcare professional. Side effects may also be reported to:

DISPOSAL

Used needles must be disposed of in an approved sharps container. Do not dispose of needles in household waste.

PRODUCT IDENTIFICATION

Product Code: ZTX-TIR60-VIAL

MANUFACTURER ZENTRIX®

Switzerland

www.labszentrix.com

REGULATORY DOCUMENT REFERENCE

IFU Code: ZTX-TIR60-EN-V1.0

Revision Date: 2026

Advanced Peptide Systems

Manufactured in Switzerland

© 2026

ZENTRIX®

ZENTRIX®

